Abstract
The 10-year survival for patients with metastatic melanoma is less than 10%. 1 Balch CM Gershenwald JE Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27: 6199-6206 Crossref PubMed Scopus (3603) Google Scholar After decades of failed attempts to improve treatment outcomes in patients with this disease, 2 Bhatia S Tykodi SS Thompson JA Treatment of metastatic melanoma: an overview. Oncology. 2009; 23: 488-496 PubMed Google Scholar the recent successes with ipilimumab and the inhibitors of BRAF and MEK (vemurafenib, dabrafenib, and trametinib) have ushered in a new era in systemic therapy. 3 Bhatia S Thompson JA Systemic therapy for metastatic melanoma in 2012: dawn of a new era. J Natl Compr Canc Netw. 2012; 10: 403-412 PubMed Google Scholar , 4 Hodi FS O'Day SJ McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723 Crossref PubMed Scopus (10966) Google Scholar , 5 Chapman PB Hauschild A Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516 Crossref PubMed Scopus (6022) Google Scholar , 6 Flaherty KT Infante JR Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367: 1694-1703 Crossref PubMed Scopus (2101) Google Scholar , 7 Flaherty KT Robert C Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367: 107-114 Crossref PubMed Scopus (1681) Google Scholar These breakthroughs have not only provided more treatment options for patients with melanoma, but have also spurred the investigation of a new generation of drugs for cancer therapy. In The Lancet, Caroline Robert and colleagues 8 Robert C Ribas A Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014; (published online July 15.)http://dx.doi.org/10.1016/S0140-6736(14)60958-2 PubMed Google Scholar report the results of programmed-death-receptor-1 (PD-1) blockade with pembrolizumab (MK-3475) in patients with melanoma previously treated with an anti-cytotoxic T-lymphocyte-associated-antigen-4 (CTLA-4) antibody ipilimumab; these findings are another important advance in the rapidly evolving landscape of cancer immunotherapy. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialThe results suggest that pembrolizumab at a dose of 2 mg/kg or 10 mg/kg every 3 weeks might be an effective treatment in patients for whom there are few effective treatment options. Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
